drugset / Trial / NCT01921712

A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

NCT01921712 ↗

Phase 1 Completed 38 enrolled Pulmatrix Inc. Quotient Clinical · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of PUR0200. In addition, the study will look at the blood levels of different doses of PUR0200 and their affect on lung function in COPD patients.

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PUR0200 Unknown — Inhaled